Baspeyras Martine, Dallara Jean-Marie, Cartier Hugues, Charavel Marie-Hélène, Dumas Laurent
Centre Bordelais Dermatologie Esthetique, Bordeaux, France.
Centre Laser Dermatologique Laser MD, Strasbourg, France.
J Cosmet Dermatol. 2017 Sep;16(3):342-347. doi: 10.1111/jocd.12335. Epub 2017 Jul 4.
Jawline reshaping by replacing volume has become an indispensable component of modern facial rejuvenation.
To evaluate calcium hydroxylapatite (CaHA) for the treatment of an aging jawline in a routine setting.
Five investigators enrolled 35 subjects requesting jawline rejuvenation with CaHA. Injections were performed according to investigators usual practice. Baseline and post-treatment scores were evaluated using Merz Aesthetics Scales®. Follow-up visits took place at Day 30 (Day 60 for those with touch-up at Day 30), 180, and 360. Physician and patient satisfaction, esthetic impact of treatment, and adverse events were recorded.
Improvements in jawline contour compared with baseline were statistically significant at each visit, with scores of 2.42 (moderate to severe sagging) at baseline, 1.02 (mild) at Day 30/60 (P≤.0001), 1.11 at Day 180 (P≤.0001), and 1.45 at Day 360 (P=.0015). Statistically significant improvements in marionette line scores were also observed. Investigators rated results as "improved" to "very much improved" in all subjects up to Day 180, and in 81% of subjects at Day 360. Satisfaction with treatment was very high. Adverse events were mostly mild and related to either the procedure or injection technique.
CaHA is a very effective agent for restoring jawline contour in routine practice and is associated with high levels of physician and patient satisfaction.
通过填充容量来重塑下颌轮廓已成为现代面部年轻化不可或缺的一部分。
在常规环境中评估羟基磷灰石(CaHA)治疗下颌轮廓老化的效果。
五名研究人员招募了35名要求使用CaHA进行下颌轮廓年轻化的受试者。注射按照研究人员的常规操作进行。使用Merz美学量表®评估基线和治疗后的评分。在第30天(第30天进行补打的患者为第60天)、180天和360天进行随访。记录医生和患者的满意度、治疗的美学效果以及不良事件。
与基线相比,每次随访时下颌轮廓的改善均具有统计学意义,基线评分为2.42(中度至重度下垂),第30/60天为1.02(轻度)(P≤.0001),第180天为1.11(P≤.0001),第360天为1.45(P=.0015)。在木偶纹评分方面也观察到具有统计学意义的改善。在第180天之前,所有受试者的研究人员将结果评为“改善”至“非常显著改善”,在第360天,81%的受试者也是如此。对治疗的满意度非常高。不良事件大多为轻度,与手术或注射技术有关。
在常规实践中,CaHA是恢复下颌轮廓的非常有效的药物,并且医生和患者的满意度很高。